Cantor Fitzgerald Reaffirms Neutral Rating for Humana (NYSE:HUM)

Cantor Fitzgerald restated their neutral rating on shares of Humana (NYSE:HUM) in a research report released on Monday, Benzinga reports. Cantor Fitzgerald currently has a $395.00 price target on the insurance provider’s stock.

HUM has been the topic of several other research reports. Baird R W raised Humana to a hold rating in a research report on Thursday, May 30th. Royal Bank of Canada dropped their target price on Humana from $415.00 to $353.00 and set an outperform rating on the stock in a research report on Thursday, April 25th. Deutsche Bank Aktiengesellschaft increased their target price on Humana from $341.00 to $349.00 and gave the company a hold rating in a research report on Friday, August 2nd. Robert W. Baird began coverage on Humana in a research report on Thursday, May 30th. They set a neutral rating and a $374.00 target price on the stock. Finally, Bank of America increased their target price on Humana from $342.00 to $376.00 and gave the company a neutral rating in a research report on Monday, May 20th. Thirteen research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Humana currently has a consensus rating of Hold and an average target price of $396.35.

Humana Trading Up 0.4 %

HUM opened at $358.55 on Monday. The stock’s fifty day moving average is $367.91 and its two-hundred day moving average is $346.43. The company has a market capitalization of $43.21 billion, a P/E ratio of 22.33, a PEG ratio of 2.09 and a beta of 0.51. Humana has a 52 week low of $298.61 and a 52 week high of $530.54. The company has a quick ratio of 1.67, a current ratio of 1.66 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping the consensus estimate of $5.89 by $1.07. The company had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. Humana’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the business posted $8.94 EPS. Analysts forecast that Humana will post 16.14 earnings per share for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a yield of 0.99%. Humana’s dividend payout ratio (DPR) is 22.04%.

Hedge Funds Weigh In On Humana

A number of institutional investors have recently modified their holdings of the stock. Wallace Advisory Group LLC raised its stake in shares of Humana by 25.0% during the 2nd quarter. Wallace Advisory Group LLC now owns 851 shares of the insurance provider’s stock valued at $318,000 after buying an additional 170 shares during the last quarter. Sunbelt Securities Inc. raised its stake in shares of Humana by 181.0% during the 2nd quarter. Sunbelt Securities Inc. now owns 163 shares of the insurance provider’s stock valued at $61,000 after buying an additional 105 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of Humana by 113.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 5,619 shares of the insurance provider’s stock valued at $2,099,000 after buying an additional 2,986 shares during the last quarter. NewEdge Advisors LLC raised its stake in shares of Humana by 44.8% during the 2nd quarter. NewEdge Advisors LLC now owns 5,984 shares of the insurance provider’s stock valued at $2,236,000 after buying an additional 1,851 shares during the last quarter. Finally, Creative Planning raised its stake in shares of Humana by 15.0% during the 2nd quarter. Creative Planning now owns 26,518 shares of the insurance provider’s stock valued at $9,909,000 after buying an additional 3,465 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.